Next Generation Sequencing: Underlying Technology and Applications to Cancer

Speaker: John Methot , Director of Health Informatics Architecture at the Dana-Farber Cancer Institute

Date: Wednesday, March 08, 2017

Time: 7:00 PM to 9:00 PM Note: all times are in the Eastern Time Zone

Public: Yes

Location: Broad Institute Auditorium

Event Type:

Room Description:

Host: Peter Mager, p.mager AT computer.org

Contact: Dorothy Curtis, dcurtis@csail.mit.edu

Relevant URL: http://ewh.ieee.org/r1/boston/computer/

Speaker URL: None

Speaker Photo:
None

Reminders to: seminars@csail.mit.edu

Reminder Subject: TALK: Next Generation Sequencing: Underlying Technology and Applications to Cancer

*IEEE Computer Society and GBC/ACM*

*7:00 PM, Wednesday, March 8, 2017*

*Broad Institute Auditorium, 415 Main St, Cambridge*

*Next Generation Sequencing: Underlying Technology and Applications to Cancer*

*John Methot*

*Director of Health Informatics Architecture at the Dana-Farber Cancer Institute*

Abstract: The development of DNA sequencing technology was spurred by the Human Genome Project in the 1990s resulting in massively parallel techniques that are referred to as Next Generation Sequencing. Introduced in 2006, these and subsequent technologies have revolutionized biology. Hundreds of organisms have complete reference genomes. Hundreds of thousands of humans have been sequenced. Myriad creative adaptations of sequencing have been and continue to be devised. Sequencing is now a routine technique that is at the core of biological research in academia, industry and medicine and increasingly in medical care itself.

Precision Medicine is the concept that differences in disease risk, prognosis, and response to treatment can be elucidated at the molecular level, often using nucleic acid sequencing. While it is expected to impact many diseases precision medicine has had its earliest applications and successes in cancer. The identification of specific DNA alterations that segment what were previously considered similar tumors has lead to the development of alteration-specific drugs called targeted therapies.

This presentation will include a brief history of sequencing technology and a description of how sequencing is performed, how the large volume of resulting data is analyzed, and a brief survey of the ever-growing collection of applications. Then we'll focus on the main application in cancer, somatic variant identification, and its use in clinical care.

John Methot is a software and systems architect with more than 30 years' experience developing applications in scientific and technical domains. Since 2006 his work has focused on genomics in the life sciences in pharmaceutical and biotech research and most recently in clinical cancer research. He holds a BS in Computer Science from the University of Washington and a Masters in Bioinformatics from the University of Illinois, Chicago. He is currently the Director of Health Informatics Architecture at the Dana-Farber Cancer Institute, and is also a co-organizer of the BostonComputational Biology and Bioinformatics group with over 1300 members.

This joint meeting of the Boston Chapter of the IEEE Computer Society and GBC/ACM will be held in the Broad Institute Auditorium (MIT building NE-30). The Broad Institute is at 415 Main St between Vassar and Ames streets. You can see it on a map at this location. http://whereis.mit.edu/map-jpg?zoom=level2&centerx=710846&centery=496467&oldzoom=level3&map.x=340&map.y=72 The auditorium is on the ground floor near the entrance.

Up-to-date information about this and other talks is available online at http://ewh.ieee.org/r1/boston/computer/. You can sign up to receive updated status information about this talk and informational emails about future talks at http://mailman.mit.edu/mailman/listinfo/ieee-cs, our self-administered mailing list.

For more information contact Peter Mager (p.mager at computer.org )

Research Areas:

Impact Areas:

See other events that are part of the Boston IEEE/ACM Joint Seminar Series 2016/2017.

Created by Dorothy Curtis at Friday, February 10, 2017 at 3:09 PM.